Enterprise Value
93.36M
Cash
83.96M
Avg Qtr Burn
-4.654M
Short % of Float
10.46%
Insider Ownership
0.06%
Institutional Own.
21.77%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
(Z)-endoxifen Details Cancer, Carcinoma | Phase 2 Data readout | |
(Z)-endoxifen + Abemaciclib (VERZENIO®) Details Cancer, Breast cancer | Phase 2 Data readout | |
AT-301 Details COVID-19 | Failed Discontinued | |
AT-H201 Details COVID-19 | Failed Discontinued |